Stock P09 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pacific Biosciences of California, Inc. Börse Stuttgart

Equities

P09

US69404D1081

Market Closed - Börse Stuttgart
Other stock markets
 14:42:05 05/07/2024 BST 		After market 21:00:09
1.199 EUR +0.87% Intraday chart for Pacific Biosciences of California, Inc. 1.204 +0.38%
07-01 Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 3000E Growth Index CI
07-01 Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2000 Growth Index CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company appears to be poorly valued given its net asset value.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 4.38 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock Pacific Biosciences of California, Inc.
-87.08% 354M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+1.75% 204B
B
DANAHER CORPORATION Stock Danaher Corporation
+3.42% 178B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+31.54% 154B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+32.16% 112B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.71% 64.32B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+21.08% 54.88B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-1.61% 47.24B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-9.11% 36.8B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.34% 35.26B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PACB Stock
  4. P09 Stock
  5. Ratings Pacific Biosciences of California, Inc.